NGS-Based Products for Oncology Research

Overview

The field of molecular oncology has witnessed tremendous progress in the past decade, thanks to advancements in technologies such as next generation sequencing (NGS) and liquid biopsy, a non-invasive sampling method that offers the potential for new applications in oncology research.

Roche Sequencing Solutions offers complete NGS ctDNA and tumor tissue assay kits and reagents for oncology research applications.

Assays	Product	Benefits
AVENIO family of NGS Oncology Assays* A uniquely versatile solution for comprehensive tumor profiling, monitoring and concordance analysis.	AVENIO ctDNA Analysis Kits AVENIO ctDNA Targeted Kit Tumor profiling AVENIO ctDNA Expanded Kit Expanded tumor profiling AVENIO ctDNA Surveillance Kit Longitudinal tumor burden monitoring AVENIO Tumor Tissue Analysis Kits AVENIO Tumor Tissue Targeted Kit Tumor profiling AVENIO Tumor Tissue Expanded Kit Expanded tumor profiling AVENIO Tumor Tissue Surveillance Kit Longitudinal tumor burden monitoring	Portfolio of assays provide flexibility to match the right test to the right research goal Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay Exceptional analytical performance backed by robust data^2,3 End-to-end workflow from extraction to analysis and reporting in five days

Assays

Product

Benefits

AVENIO family of NGS Oncology Assays*

A uniquely versatile solution for comprehensive tumor profiling, monitoring and concordance analysis.

AVENIO ctDNA Analysis Kits

AVENIO ctDNA Targeted Kit
Tumor profiling

AVENIO ctDNA Expanded Kit
Expanded tumor profiling

AVENIO ctDNA Surveillance Kit
Longitudinal tumor burden monitoring

AVENIO Tumor Tissue Analysis Kits

AVENIO Tumor Tissue Targeted Kit
Tumor profiling

AVENIO Tumor Tissue Expanded Kit
Expanded tumor profiling

AVENIO Tumor Tissue Surveillance Kit
Longitudinal tumor burden monitoring

Portfolio of assays provide flexibility to match the right test to the right research goal
Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹
All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
Exceptional analytical performance backed by robust data^2,3
End-to-end workflow from extraction to analysis and reporting in five days

Reagents	Products	Benefits
Sample QC Reagents*	KAPA hgDNA Quantification & QC Kits	Reliable quantification and quality assessment of low-input or FFPE samples to optimize library construction yields and workflows
Target Enrichment Reagents*	KAPA HyperChoice (human designs) KAPA HyperExplore (non-human designs) KAPA HyperCap Workflow v3	Reduce sequencing costs and save time with superior capture uniformity Demonstrated design expertise, 10+ years of experience Reliably enrich challenging, previously inaccessible genomic regions Streamline targeted sequencing with HyperCap workflow v3
Library Preparation Reagents*	KAPA HyperPrep Kits KAPA HyperPlus Kits KAPA HTP/LTP Library Preparation Kits	High-quality library construction from FFPE and challenging samples in less than 3 hours Low bias enzymatic fragmentation for construction of high-quality libraries from microbes with extreme genomic GC content
Library Amplification Reagents*	KAPA Library Amplification Kit	Minimal amplification bias for improved sequencing coverage in WGS workflows that require library amplification
Library Quantification Reagents*	KAPA Library Quantification Kits	Accurate quantification of adapter-ligated molecules prior to sample pooling and cluster generation or template preparation for optimal sequencing results

Instruments	Product	Benefits
Sample Collection	AVENIO Millisect System	Maximize clinical utility of tissue samples by identifying mutations missed with manual dissection and reducing false negative rates^3,4 Increase dissection efficiency and optimize results by capturing clinically relevant cells³ Improve lab workflow and minimize demands on staff by ensuring consistent sample capture through an automated, digitally assisted process

Instruments

Product

Benefits

Sample Collection

AVENIO Millisect System

Maximize clinical utility of tissue samples by identifying mutations missed with manual dissection and reducing false negative rates^3,4
Increase dissection efficiency and optimize results by capturing clinically relevant cells³
Improve lab workflow and minimize demands on staff by ensuring consistent sample capture through an automated, digitally assisted process

References

National Comprehensive Cancer Network. October 15, 2016.
Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555.
Geiersbach K, Ady N, Welker N, et al. Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors. Cancer Genetics. 2016;209(1-2):42- 49. 2.
Gustafson H, Theiss N, Hnatyszyn JH. Characterizing heterogeneic tumor profiles with an integrated companion diagnostics approach. Integrative Cancer Science and Therapeutics. 2016;3(4):500-503.
Data on file.

*Research Use Only. Not for use in diagnostic procedures.

AVENIO, KAPA, SEQCAP and MILLISECT are trademarks of Roche. Other product names and trademarks are the property of their respective owners.